SC
DFTX

Shay Capital’s Definium Therapeutics DFTX Stock Holding History

Shay Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189K Buy
+10,000
New +$170K 0.02% 393
2021
Q3 		– Sell
-7,867
Closed -$407K – 644
2021
Q2 		$407K Buy
+7,867
New +$413K 0.05% 289

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Shay Capital's DFTX Position: Q4 2021 in Review

Shay Capital sold out of Definium Therapeutics (DFTX) in Q4 2021, closing a stake of 9,417 shares — an estimated $329K sold.

Shay Capital first reported a position in DFTX in Q2 2021 and held it in 2 quarters. The position peaked at $588K in Q2 2021. 176 funds tracked by Wall St. Rank hold DFTX as of Q4 2021.

  • Shay Capital reported no remaining Definium Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Shay Capital sold 9,417 Definium Therapeutics shares in Q4 2021, an estimated $329K.
  • Shay Capital first reported a position in Definium Therapeutics in Q2 2021 and held it in 2 quarters.
  • Shay Capital's Definium Therapeutics position peaked at $588K in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2021.

Based on Shay Capital's 13F filing for Q4 2021, filed 14 Feb 2022.